This report was first published by Endpoints News. To see the original version, click here
Novartis is the latest drugmaker to invest in its Chinese footprint, with a pledge of more than 3.3 billion yuan ($480 million) to bolster two manufacturing and R&D sites.
The company will pour 1.5 billion yuan ($218 million) into expanding its tablets and capsules site in the Changping district of Beijing, according to a Sunday release in Chinese. Around 1.8 billion yuan ($262 million) will go to launching the “second phase” of the drugmaker’s China headquarters and R&D facility in Shanghai. It wasn’t clear what that phase entailed, and Novartis didn’t immediately comment before publication.
您已阅读34%（688字），剩余66%（1324字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。